INTRODUCTION
B-type natriuretic peptide (BNP) is widely used to diagnose and assess heart failure prognosis. However, its effects on pathological cardiomyocyte hypertrophy and the underlying mechanisms remain largely unexplored.
Methods
Here, we report the use of isoproterenol (ISO)-induced cardiomyocyte hypertrophy models with varying doses of BNP to investigate the potential targets and molecular mechanisms of BNP in rat cardiomyocyte hypertrophy.
Results
Phenotypic measurement confirmed that BNP treatment significantly attenuated ISOinduced cardiomyocyte hypertrophy. Transcriptomic profiling of cardiomyocytes identified key markers and pathways associated with hypertrophy and BNP intervention, revealing that BNP could broadly reverse ISO-induced molecular perturbations. Trajectory analysis and network module analysis further highlighted MyD88 and Pik3r3 as candidate regulatory nodes associated with BNP intervention. BNP treatment potentially downregulates these genes, which is accompanied by reduced activity of inflammatory and growth-related signaling networks. These changes are associated with pathways involved in sarcomeric protein synthesis, immune-inflammatory responses, myocardial fibrosis, mitochondrial homeostasis, and oxidative stress, suggesting a potential role for BNP in attenuating cardiomyocyte hypertrophy.
Discussion
These findings suggest that BNP may exert protective effects against cardiomyocyte hypertrophy through coordinated modulation of multiple signaling pathways. MyD88- and Pik3r3- associated networks emerged as potential molecular mechanisms underlying BNP-mediated responses and may represent promising targets for future investigation.
Conclusion
This study provides transcriptomic evidence that BNP may attenuate cardiomyocyte hypertrophy and identifies MyD88- and Pik3r3-associated signaling networks as potential molecular mediators of this response. These findings suggest possible mechanisms underlying the protective effects of BNP and provide a foundation for future functional validation studies in hypertrophic heart disease.
S100A8/S100A9 emerges as a central mediator linking hyperglycemia‐induced oxidative stress, metabolic inflexibility, and fibrotic reprogramming of CPCs, thereby promoting diabetic heart failure and may serve as a biomarker and therapeutic target at the interface of immunometabolism, cardiac regeneration, and cardio‐onc...
BACKGROUND
The role of Klotho in heart failure (HF) and its underlying metabolic mechanisms remain unclear. This study investigated how Klotho deficiency affects extracellular matrix (ECM) homeostasis and metabolic regulation in post-myocardial infarction HF (MI-HF), with a focus on aldehyde dehydrogenase 1 family memb...
Bing Zhao, Chun Xiao· Experimental Gerontology· 0 citations
A novel mechanism by which ACSL4 fuels PASMC growth in PH through reshaping fatty acid metabolism and targeting the VGLL4/YAP signaling axis is uncovers.
Wei Chen, Yi-Ting Dong, Qiong Shi et al.· Vascular pharmacology· 0 citations
The results nominate testable macrophage regulatory and signaling hypotheses for HFpEF but do not establish drug-specific reversal or cross-model conservation.
Ding-Kun Wang, Wenyao Cai, Ruonan Wang et al.· Omics· 0 citations
Hypertension-induced cardiac fibrosis is a major risk factor for heart failure; although disrupted mitochondrial homeostasis has been confirmed to serve a critical role in the pathological process, its upstream regulatory factors remain incompletely understood. In the current study, RNA sequencing and bioinformatics an...
Yong-Bo Ma, Xiao-Zhe Chen, Zi-Xian Liu et al.· Molecular Medicine Reports· 0 citations
Pathological cardiac hypertrophy is maladaptive cardiac remodeling induced by chronic adverse stimuli. In this study, the E3 ubiquitin ligase RNF128 was identified as a suppressor of pathological cardiac dysfunction with therapeutic value. Methods The expression of Ring Finger protein 128 (RNF128) in pathological cardi...